In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline Pharmaceuticals Ltd.

http://www.gsk-india.com

Latest From GlaxoSmithKline Pharmaceuticals Ltd.

Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut

Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.

Pricing Debate Legislation

GSK Makes ADC Pipeline Comeback With Mersana Deal

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.

Companies Deals

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

Ipsen’s Onivyde SCLC Dreams Die With Phase III Failure, Focus Shifts To Pancreatic

The French firm’s Onivyde has missed the mark in an advanced small-cell lung cancer Phase III trial, prompting the firm to tout the drug’s prospects in a large pancreatic cancer indication instead.

Clinical Trials Cancer
See All

Company Information

UsernamePublicRestriction

Register